摘要
目的 探讨脑钠肽（BNP）及C-反应蛋白（CRP）在慢性肾衰竭（CRF）合并慢性心力衰竭（CHF）患者的诊断和判断预后的意义.方法 选取CRF合并CHF患者69例作为观察组,单纯CHF患者40例作为对照组A,再选取同期健康体检者40例作为对照组B,分别检测并对比三组受试者治疗前后BNP、CRP水平及观察组患者治疗前后不同CKD分期、NYHA分级时BNP、CRP水平变化.结果 观察组、对照组A患者治疗前BNP、CRP水平明显高于对照组B,差异具有显著性（P＜0.05）,观察组、对照组A患者经2周治疗后BNP、CRP水平较治疗前显著降低,差异具有显著性（P＜0.05）,观察组患者治疗后及对照组A患者治疗后BNP、CRP与对照组B差异无显著性（P＞0.05）,观察组患者比较治疗前后BNP、CRP水平随NYHA分级的升高而明显增高（P＜0.05）,与CKD分期增高无相关关系（P＞0.05）.结论 血浆BNP、CRP水平变化在慢性肾衰竭（CRF）合并慢性心力衰竭（CHF）患者的诊断、疗效评价和判断预后具有重要临床价值。
Objectives the level difference of plasma BNP and CRP is of significant clinical value in the treatment,the therapeutic evaluation and the anticipation prognosis of the patients with CRF and CHF.Methods The method of to select 69 patients with CRF and CHF as the observing team,in contrast to the team A of 40 patients with CHF only,team B of the healthy check-up,comparing the level difference of BNP and CRP of the patients in these three groups before and after treatment.Results As a result,the BNP and CRP level is much higher in observing team and team A than in team B,and the difference is significant （P 〈 0.05）;while after two-week treatment,they have increasingly lowered,the difference is distinctive （P 〈0.05）.The difference of the patients in group A and observing is not significant（P 〉0.05）,and the level of BNP and CRP of these two groups has remarkably increased with the classification of NYHA （P 〈 0.05）,irrelevant to the increasing CKD（P 〉 0.05）.Conclusions The level difference of plasma BNP and CRP is of significant clinical value in the treatment,the therapeutic evaluation and the anticipation prognosis of the patients with CRF and CHF.
出处
《国际泌尿系统杂志》
2015年第6期899-902,共4页
International Journal of Urology and Nephrology
关键词
肾功能衰竭
慢性
心力衰竭
利钠肽
脑
C反应蛋白质
Kidney Failure,Chronic
Heart Failure
Natriuretic Peptide,Brain
C-Reactive Protein
